REFERENCES / SOURCE SHEET
Keep the source in view.
This page lists the sources cited in the guide. They are records from FDA, the U.S. drug regulator, and an approved drug label. Some are technical documents. The notes tell you which question each source addresses, so a link has a clear purpose.
NXT LVL may earn money when readers become Promise patients.
Promise prescribes now. A licensed U.S. provider reviews each request and decides whether to prescribe. Not everyone qualifies. Compounded medicines are made to order and are not FDA-approved.
U.S. patients only. Availability varies by state and by treatment. Promise does not offer care outside the U.S.
Where our facts come from.
- FDA review of CJC-1295
The different CJC-1295 forms, the human studies and the limits of the evidence.
- FDA review of ipamorelin
What ipamorelin is, which human studies exist and which safety questions remain.
- FDA peptide ingredient safety listings
The withdrawn nominations and the separate safety listing for ipamorelin acetate.
- FDA records for sermorelin
The earlier approved products and their discontinued status. The linked record is technical.
- Current approved tesamorelin drug label
The specific approved use, limits of use, safety warnings and provider checks.
Match the source to the claim.
A small human study can describe a hormone response without establishing a result for training or recovery. A drug label applies to its specific finished product and indication, meaning its approved use. A compounding listing describes ingredient rules; it is not an approval of a medicine.
FDA's ingredient safety page used here is marked current as of April 22, 2026. It does not publish individual dates for withdrawn nominations. The guide does not assign dates that the record cannot support.
What these links cannot answer.
They cannot establish personal eligibility or make a combination equivalent to an approved product. The side-by-side notes and beginner questions give the plain-language context. Promise lists these options for provider review. A licensed U.S. provider decides whether to prescribe. The listing does not change FDA status or the rules for the exact ingredient.
Put the next step in licensed hands.
A Promise visit starts a request for review. A licensed U.S. provider decides whether to prescribe. Not everyone qualifies, and no particular treatment is promised.
NXT LVL may earn money when readers become Promise patients.
Promise prescribes these peptides now through licensed U.S. providers. A provider reviews every request and decides. Not everyone qualifies.
U.S. patients only. Availability varies by state and by treatment. Promise does not offer care outside the U.S.